Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200955 | 0.89 | TSHR (0.40) | TSHRL3MBTL1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5702143 | 0.83 | SMN1; SMN2 (0.36) | L3MBTL1SMN1; SMN2DRD2DRD3MEN1 | |
| SCHEMBL2650519 | 0.73 | TSHR (0.42) | TSHRL3MBTL1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5702071 | 0.72 | SMN1; SMN2 (0.39) | L3MBTL1SMN1; SMN2DRD2DRD3MEN1 | |
| SCHEMBL5701993 | 0.72 | SMN1; SMN2 (0.36) | L3MBTL1SMN1; SMN2DRD2DRD3MEN1 | |
| SCHEMBL29844444 | 0.70 | TSHR (0.39) | TSHRL3MBTL1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5280126 | 0.69 | HPGD (0.46) | TSHRL3MBTL1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2656551 | 0.69 | AR (0.40) | ALDH1A1HPGDAR | |
| SCHEMBL2657027 | 0.69 | AR (0.34) | TSHRALDH1A1HPGDARMEN1 | |
| SCHEMBL21910132 | 0.68 | MPO (0.38) | TSHRBCAT1L3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3110820-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10196390-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-3110820-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015131080-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196390-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TSHR 1652/4885BCAT1 985/4885L3MBTL1 914/4885 |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TSHR 1652/4885BCAT1 985/4885L3MBTL1 914/4885 |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TSHR 1652/4885BCAT1 985/4885L3MBTL1 914/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TSHR 1652/4885BCAT1 985/4885L3MBTL1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.